Gillette-Guyonnet, Sophie, Andrieu, Sandrine, Dantoine, Thierry, Dartigues, Jean-François, Touchon, Jacques, Vellas, B.

Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]

Sampson, Elizabeth L., Jones, Louise, Thuné-Boyle, Ingela C. V., Kukkastenvehmas, Riitta, King, Michael, Leurent, Baptiste, Tookman, Adrian, Blanchard, Martin R.

Patients with advanced dementia often receive poor end-of-life care. We aimed to design and pilot a palliative care and advance care plan (ACP) intervention. Patients had undergone emergency hospital admission and had severe dementia. The intervention consisted of a palliative care patient assessment which informed an ACP discussion with the carer, who was offered the […]

Meinert, Curtis L., McCaffrey, Lee D., Breitner, John C. S.

Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]

Kimura, Takemi, Hayashida, Hideki, Furukawa, Hitomi, Takamatsu, Junichi

The aim of the present study was to investigate the efficacy of Yokukansan in improving behavioral symptoms of frontotemporal dementia. This study was a prospective, open-label trial of daily Yokukansan for 4 weeks in 20 frontotemporal dementia patients. Yokukansan treatment was found to significantly improve scores for the Neuropsychiatric Inventory and the Stereotypy Rating Inventory. […]

Aarsland, Dag, Ballard, Clive, Walker, Zuzana, Bostrom, Fredrik, Alves, Guido, Kossakowski, Katja, Leroi, Iracema, Pozo-Rodriguez, Francisco, Minthon, Lennart, Londos, Elisabet

Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]